• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

157.69 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10
Open 157.69
Bid (Size) 138.21 (100)
Ask (Size) 159.21 (100)
Prev. Close 157.69
Today's Range 157.69 - 157.69
52wk Range 57.99 - 200.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
July 06, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
July 06, 2026
From Belite Bio, Inc
Via GlobeNewswire

Performance

YTD
-1.0%
-1.0%
1 Month
+12.9%
+12.9%
3 Month
-7.1%
-7.1%
6 Month
-1.6%
-1.6%
1 Year
+169.0%
+169.0%

More News

Read More
News headline image
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
June 12, 2026
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Inc - ADR (NASDAQ:BLTE) Reports Narrower-Than-Expected Q4 Loss, NDA Submission on Track for 2026 ↗
March 02, 2026
Via Chartmill
News headline image
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 02, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Q1 Earnings Call Highlights ↗
May 20, 2026
Via MarketBeat
Topics Earnings
News headline image
Belite Bio (BLTE) Q1 2026 Earnings Transcript ↗
May 20, 2026
Via The Motley Fool
News headline image
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
May 20, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
May 18, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
May 13, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
April 27, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Participate in Four Upcoming Investor Conferences
April 23, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
April 22, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
April 21, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 31, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript ↗
March 03, 2026
Via The Motley Fool
Topics Earnings
News headline image
Belite Bio to Participate in the Leerink Global Healthcare Conference
March 02, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 02, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
January 29, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
January 27, 2026
From Belite Bio, Inc
Via GlobeNewswire
InvestorNewsBreaks – Belite Bio, Inc (NASDAQ: BLTE) Prices $350M Underwritten Public Offering of ADSs
December 05, 2025
Via Investor Brand Network

Frequently Asked Questions

Is Belite Bio, Inc - American Depositary Shares publicly traded?
Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.
What exchange does Belite Bio, Inc - American Depositary Shares trade on?
Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?
The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market
What is the current price of Belite Bio, Inc - American Depositary Shares?
The current price of Belite Bio, Inc - American Depositary Shares is 157.69
When was Belite Bio, Inc - American Depositary Shares last traded?
The last trade of Belite Bio, Inc - American Depositary Shares was at 07/07/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap